|
Alzheimer's Disease
|
0.110 |
Biomarker
|
disease |
BEFREE |
γ-Secretase is an intramembrane-cleaving protease that generates the toxic species of the amyloid-β peptide (Aβ) that is responsible for the pathology of Alzheimer disease.
|
31527118 |
2019 |
|
Alzheimer's Disease
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
|
24162737 |
2013 |
|
Alzheimer's Disease
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
|
24162737 |
2013 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Estradiol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association Study of Eight Steroid Hormones and Implications for Sexual Dimorphism of Coronary Artery Disease.
|
31169883 |
2019 |
|
Estradiol level result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association Study of Eight Steroid Hormones and Implications for Sexual Dimorphism of Coronary Artery Disease.
|
31169883 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
|
29844566 |
2018 |
|
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study.
|
28107422 |
2017 |
|
Neutrophil count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration.
|
26561523 |
2016 |
|
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease.
|
23969696 |
2013 |
|
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease.
|
23969696 |
2013 |
|
fibrinogen activity
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease.
|
23969696 |
2013 |
|
Fibrinogen, CTCAE
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease.
|
23969696 |
2013 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, we believe that SPPL2a represents an interesting and druggable pharmacological target, potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.
|
29359565 |
2018 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
The intramembrane protease signal peptide peptidase-like 2a (SPPL2a) is a potential drug target for the treatment of autoimmune diseases due to an essential role in B cells and dendritic cells.
|
28731783 |
2017 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Nevertheless, inhibition of SPPL2a has been suggested as novel approach to target B cells for treating autoimmunity.
|
25035924 |
2014 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Positive staining for IMP-3 was observed in 74% (71/96) of the tumors.
|
22012575 |
2012 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
IMP-3, a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein (IMP) family, is expressed mainly during embryonic development and in some tumors.
|
15753088 |
2005 |
|
Merkel cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The CT antigens SP-17, IMP-3, and TMEFF1 were selected using transcriptome profiling to identify CT antigens expressed in MCC tumors.
|
31218705 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of IMP-3 expression pattern in esophageal squamous cell carcinoma.
|
31656650 |
2019 |
|
Mycobacterium Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that inherited SPPL2a deficiency in humans underlies mycobacterial disease by decreasing the numbers of cDC2s and impairing IFN-γ production by mycobacterium-specific memory T<sub>H</sub>1* cells.
|
30127434 |
2018 |
|
Epithelioid mesothelioma, malignant
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the immunohistochemical analysis, Noxa showed sensitivity of 69.0%, specificity of 93.6% and positive predictive value of 93.0% as a positive marker of EM in distinguishing it from RMH, and these values were almost similar to IMP-3.
|
26735863 |
2016 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Multiple studies have linked high expression of IMP proteins, and especially of IMP-3, to an unfavorable prognosis in numerous types of cancer.
|
23812426 |
2014 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Multiple studies have linked high expression of IMP proteins, and especially of IMP-3, to an unfavorable prognosis in numerous types of cancer.
|
23812426 |
2014 |